RESUMEN
These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA. This will help promote the appropriate use of PET imaging and contribute to evidence-based medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374-80, 2006), and supplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199-208, 2016). The information provided should be taken in the context of local conditions and regulations.
Asunto(s)
Aminoácidos , Fluorodesoxiglucosa F18 , Glioma/diagnóstico por imagen , Medicina Nuclear , Tomografía de Emisión de Positrones/normas , Guías de Práctica Clínica como Asunto , Sociedades Médicas , Adulto , Niño , Humanos , Procesamiento de Imagen Asistido por Computador , Marcaje Isotópico , Control de Calidad , Recurrencia , Estándares de Referencia , Proyectos de InvestigaciónRESUMEN
Obtaining drugs for use in basic and preclinical research has become increasingly difficult and in many instances is dependent upon the company's interest in the proposed research. In this paper, we describe a simple procedure for extracting the antidepressants sertraline, paroxetine, fluoxetine, venlafaxine, citalopram, escitalopram, duloxetine and atomoxetine from their readily available pharmaceutical preparations. With the exception of citalopram, escitalopram and duloxetine in which the free base was the final product, the hydrochloride salt forms of these drugs were prepared. This procedure provides these antidepressants in gram quantities in recovered yields ranging from 53% to 100% at over 99% purity and is in principle applicable to other drugs as well.